Bliss Biopharmaceutical (Hangzhou) Co., Ltd. (hereinafter referred to as “BlissBio”), founded in Qiantang Area, Hangzhou, Zhejiang Province in December 2017 by a number of American PhDs, is a clinical-stage national high-tech biopharmaceutical enterprise with independent intellectual properties that focuses on R&D and commercialization of anti-tumor macromolecular biotherapeutics. Since its foundation, guided by unmet clinical needs and based on rich experience accumulated in industrial R&D full life cycle of new medications, centering around multiple oncology indications, with continuous development and layout of gradient product pipeline of differentiated macromolecular biological innovative drugs, and through independent R&D and external cooperation as well, BlissBio has established and improved its multi-tech platforms, as well as independent capacity of production of antibody and ADC that meet international GMP standards. With “Together, We Improve Human Health” as the core value, through multi-level collaborations and developments, BlissBio will continue to focus on innovative drugs to benefit patients as soon as possible.